Growth Hormone Releasing Peptides Remain Potent in Men with Induced Low Testosterone
Background
Growth hormone (GH) is crucial for metabolism, body composition, and overall well-being. Its secretion is tightly regulated by Growth Hormone-Releasing Hormone (GHRH) and Growth Hormone-Releasing Peptides (GHRPs), like GHRP-2. Conditions such as hypogonadism (low testosterone) are known to affect various endocrine axes, including potentially GH secretion. This study investigated whether the efficacy of GHRH and GHRP-2 in stimulating GH release is preserved in young men with experimentally induced hypogonadism.
Results
The study revealed that both GHRH and GHRP-2 maintained significant efficacy in stimulating GH release despite the presence of experimentally induced hypogonadism. In the eugonadal state, GHRH increased peak GH levels by an average of 8.2 ± 1.5 ng/mL, while in the hypogonadal state, it still achieved 7.9 ± 1.8 ng/mL, demonstrating no statistically significant difference (p=0.72). Similarly, GHRP-2 induced a robust GH peak of 12.5 ± 2.1 ng/mL in eugonadal men, which was remarkably preserved at 11.8 ± 2.3 ng/mL during hypogonadism (p=0.61). The most important finding was that the GH secretory responses to both GHRH and GHRP-2 were quantitatively similar in both eugonadal and experimentally induced hypogonadal states, indicating preserved pituitary responsiveness. Overall, the area under the curve (AUC) for GH secretion following GHRH was reduced by only 5% (p=0.45) and for GHRP-2 by 7% (p=0.38) in the hypogonadal state compared to eugonadal, confirming the sustained effectiveness of these peptides.
Why It Matters
This research provides crucial insights, suggesting that GH secretagogues like GHRH and GHRP-2 could be effective therapeutic options for treating GH deficiency even in individuals with co-existing hypogonadism. This is particularly relevant for conditions where both GH and testosterone levels are compromised, such as in aging or certain chronic illnesses. The preserved efficacy opens avenues for potential clinical applications, allowing for targeted GH therapy without requiring prior or concurrent testosterone normalization. Future steps should involve larger, longer-term studies in diverse populations, including older men and those with chronic hypogonadism, to confirm these findings and explore optimal dosing strategies for clinical use.